Technique information

Macromolecular crystallography is an essential tool for structural biology and the pharmaceutical industry, particularly key in the structure based drug discovery process. 

Drug discovery methods have been revolutionised by the advent of high-throughput crystallography beamlines at synchrotrons. Structure-based drug design and fragment screening methods are now a reality and widely used by the pharmaceutical industry. 

Diamond's facilities include: 

• tuneable and fixed wavelength macromolecular crystallography (MX)
• microfocus macromolecular crystallography
• high throughput data collection
• a data processing pipeline
• containment level 2 (level 3 planned)

We offer our industrial customers rapid access and flexible beamtime allocation in beamtime only, mail-in and remote access modes.

Please click on the links above to download detailed technical information. For any additional information, or to request a hard copy of any information, please contact us at industry@diamond.ac.uk or by phone on +44 1235 778797.

Service options available

We offer a range of service options for macromolecular crystallography:

• beamtime only access;
• remote access;
• mail-in data collection.

Case Studies

BioFocus and CHDI Foundation use MX at Diamond to solve structures relevant to inherited disease	Heptares Therapeutics' Xanthine-GPCR binding structures herald new Parkinson's treatments	Confocal Science are creating crystals out of this world!	Vernalis use Diamond for high throughput screening
Heptares Therapeutics use grid scans for MX	Plate screening for room temperature MX screening and data collection	HC1: a user-friendly device for crystal dehydration for MX